We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience.

Skip to main content

Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate Compared to Placebo

- Relapsing Remitting Multiple Sclerosis
- Completed

Study Title: A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

Teva Identifier: MS-GA-301 | 2009-018084-27

ClinicalTrials.gov Identifier: NCT01067521

Study Status: Completed

Trial Condition(s): Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Glatiramer acetate (GA) | Drug: Placebo

Study Description: Please refer to ClinicalTrials.gov for a description of the trial

Click for participation criteria and map of study locations

neurology icon for clinical trials

Key Participation Requirements

Gender: Female, Male

Age Range: 18 Years to 55 Years

Trial Duration: June 22, 2010 - May 12, 2017

Phase: Phase 3

Study Type

Interventional